Idiopathic Nephrotic Syndrome

How it works

Benefits

Risks & contraindications

Background

Highlighted claims

• Idiopathic nephrotic syndrome is the most common acquired glomerulopathy in children, with an incidence of 1.5–3.4 per 100,000 in Western countries. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
• Steroids achieve remission in 90% of children with nephrotic syndrome. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
• 80% of SSNS patients relapse after the first episode, and 50–60% become either steroid-dependent or frequently relapsing. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
• Steroid-dependent and frequently relapsing nephrotic syndrome patients bear high morbidity from both relapse complications and cumulative drug toxicity. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
• Anti-nephrin autoantibodies have recently been identified in childhood nephrotic syndrome, supporting a humoral autoimmune cause. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial